;PMID: 8968657
;source_file_1943.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..141] = [t:48..141]
;2)section:[e:145..155] = [t:145..155]
;3)section:[e:159..267] = [t:159..267]
;4)sentence:[e:271..510] = [t:271..510]
;5)sentence:[e:511..605] = [t:511..605]
;6)sentence:[e:606..817] = [t:606..817]
;7)sentence:[e:818..1051] = [t:818..1051]
;8)sentence:[e:1052..1120] = [t:1052..1120]
;9)sentence:[e:1121..1298] = [t:1121..1298]
;10)sentence:[e:1299..1386] = [t:1299..1386]
;11)sentence:[e:1387..1602] = [t:1387..1602]
;12)sentence:[e:1603..1711] = [t:1603..1711]
;13)sentence:[e:1712..1831] = [t:1712..1831]
;14)sentence:[e:1832..1972] = [t:1832..1972]
;15)sentence:[e:1974..2091] = [t:1974..2091]
;16)sentence:[e:2092..2215] = [t:2092..2215]
;17)sentence:[e:2216..2334] = [t:2216..2334]
;18)sentence:[e:2335..2420] = [t:2335..2420]
;19)sentence:[e:2421..2544] = [t:2421..2544]
;20)sentence:[e:2545..2674] = [t:2545..2674]
;21)sentence:[e:2675..2855] = [t:2675..2855]
;22)sentence:[e:2856..2976] = [t:2856..2976]
;23)sentence:[e:2977..3083] = [t:2977..3083]
;24)sentence:[e:3084..3219] = [t:3084..3219]
;25)sentence:[e:3220..3406] = [t:3220..3406]
;26)sentence:[e:3407..3630] = [t:3407..3630]
;27)sentence:[e:3631..3712] = [t:3631..3712]
;28)sentence:[e:3713..3822] = [t:3713..3822]
;29)sentence:[e:3823..4010] = [t:3823..4010]
;30)sentence:[e:4011..4107] = [t:4011..4107]
;31)sentence:[e:4108..4234] = [t:4108..4234]
;32)section:[e:4235..4256] = [t:4235..4256]
;33)section:[e:4260..4278] = [t:4260..4278]
;34)section:[e:4284..4290] = [t:4284..4290]
;35)section:[e:4296..4312] = [t:4296..4312]
;36)section:[e:4316..4360] = [t:4316..4360]

;section 0 Span:0..42
;Clin Pharmacokinet. 1996 Dec;31(6):444-69.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..18] Pharmacokinet) (.:[18..19] .)
        (CD:[20..24] 1996) (.:[25..31] Dec;31) (-LRB-:[31..32] -LRB-)
        (CD:[32..33] 6) (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..38] 444)
        (CD:[38..41] -69) (.:[41..42] .)))

;sentence 1 Span:48..141
;Pharmacokinetic-pharmacodynamic relationship of the selective serotonin
;reuptake  inhibitors.
;[100..140]:substance:"selective serotonin reuptake  inhibitors"
(SENT
  (NP-HLN
    (NP
      (ADJP (JJ:[48..63] Pharmacokinetic) (HYPH:[63..64] -)
            (JJ:[64..79] pharmacodynamic))
      (NN:[80..92] relationship))
    (PP (IN:[93..95] of)
      (NP (DT:[96..99] the)
         (JJ:[100..109] selective)
        (NP (NN:[110..119] serotonin) (NN:[120..128] reuptake))
        (NNS:[130..140] inhibitors)))
    (.:[140..141] .)))

;section 2 Span:145..155
;Baumann P.
(SEC
  (FRAG (NNP:[145..152] Baumann) (NNP:[153..155] P.)))

;section 3 Span:159..267
;Department Universitaire de Psychiatrie Adulte, Prilly-Lausanne, Switzerland.
; Pierre.Baumann@inst.hospvd.ch
(SEC
  (FRAG (NNP:[159..169] Department) (NNP:[170..183] Universitaire)
        (NNP:[184..186] de) (NNP:[187..198] Psychiatrie) (NNP:[199..205] Adulte)
        (,:[205..206] ,) (NNP:[207..222] Prilly-Lausanne) (,:[222..223] ,)
        (NNP:[224..235] Switzerland) (.:[235..236] .) (NNP:[238..244] Pierre)
        (NNP:[244..257] .Baumann@inst) (VBD:[257..264] .hospvd)
        (.:[264..267] .ch)))

;sentence 4 Span:271..510
;The recently introduced antidepressants, the selective serotonin reuptake 
;inhibitors (SSRIs) [citalopram, fluoxetine, fluvoxamine, paroxetine and 
;sertraline], are known for their clinical efficacy, good tolerability and 
;relative safety.
;[295..310]:substance:"antidepressants"
;[316..356]:substance:"selective serotonin reuptake  inhibitors"
;[358..363]:substance:"SSRIs"
;[366..376]:substance:"citalopram"
;[378..388]:substance:"fluoxetine"
;[390..401]:substance:"fluvoxamine"
;[403..413]:substance:"paroxetine"
;[419..429]:substance:"sertraline"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[271..274] The)
        (ADJP (RB:[275..283] recently) (VBN:[284..294] introduced))
        (NNS:[295..310] antidepressants))
      (,:[310..311] ,)
      (NP
        (NP (DT:[312..315] the)
           (JJ:[316..325] selective)
          (NML (NN:[326..335] serotonin) (NN:[336..344] reuptake))
          (NNS:[346..356] inhibitors))
        (NP (-LRB-:[357..358] -LRB-) (NNS:[358..363] SSRIs)
            (-RRB-:[363..364] -RRB-))
        (PRN (-LRB-:[365..366] -LSB-)
          (NP (NN:[366..376] citalopram) (,:[376..377] ,)
              (NN:[378..388] fluoxetine) (,:[388..389] ,)
              (NN:[390..401] fluvoxamine) (,:[401..402] ,)
              (NN:[403..413] paroxetine) (CC:[414..417] and)
              (NN:[419..429] sertraline))
          (-RRB-:[429..430] -RSB-))))
    (,:[430..431] ,)
    (VP (VBP:[432..435] are)
      (VP (VBN:[436..441] known)
        (NP-1 (-NONE-:[441..441] *))
        (PP (IN:[442..445] for)
          (PP (PRP$:[446..451] their)
            (NML
              (NML (JJ:[452..460] clinical) (NN:[461..469] efficacy))
              (,:[469..470] ,)
              (NML (JJ:[471..475] good) (NN:[476..488] tolerability))
              (CC:[489..492] and)
              (NML (JJ:[494..502] relative) (NN:[503..509] safety)))))))
    (.:[509..510] .)))

;sentence 5 Span:511..605
;They differ from each other in chemical structure, metabolism  and
;pharmacokinetic properties.
(SENT
  (S
    (NP-SBJ (PRP:[511..515] They))
    (VP (VBP:[516..522] differ)
      (PP (IN:[523..527] from)
        (NP (DT:[528..532] each) (JJ:[533..538] other)))
      (PP (IN:[539..541] in)
        (NP
          (NP (JJ:[542..550] chemical) (NN:[551..560] structure))
          (,:[560..561] ,)
          (NP (NN:[562..572] metabolism))
          (CC:[574..577] and)
          (NP (JJ:[578..593] pharmacokinetic) (NNS:[594..604] properties)))))
    (.:[604..605] .)))

;sentence 6 Span:606..817
;Therapeutic drug monitoring of these compounds  is not widely used, as the
;plasma concentration ranges within which clinical  response with minimal
;adverse effects appears to be optimal are not clearly  defined.
;[618..622]:substance:"drug"
;[643..652]:substance:"compounds"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[606..617] Therapeutic) (NN:[618..622] drug)
          (NN:[623..633] monitoring))
      (PP (IN:[634..636] of)
        (NP (DT:[637..642] these) (NNS:[643..652] compounds))))
    (VP (VBZ:[654..656] is) (RB:[657..660] not)
      (VP
        (ADVP (RB:[661..667] widely))
        (VBN:[668..672] used)
        (NP-1 (-NONE-:[672..672] *))
        (,:[672..673] ,)
        (SBAR-ADV (IN:[674..676] as)
          (S
            (NP-SBJ-2
              (NP (DT:[677..680] the)
                (NML (NN:[681..687] plasma) (NN:[688..701] concentration))
                (NNS:[702..708] ranges))
              (SBAR
                (WHPP-3 (IN:[709..715] within)
                  (WHNP (WDT:[716..721] which)))
                (S
                  (NP-SBJ
                    (NP (JJ:[722..730] clinical) (NN:[732..740] response))
                    (PP (IN:[741..745] with)
                      (NP (JJ:[746..753] minimal) (JJ:[754..761] adverse)
                          (NNS:[762..769] effects))))
                  (VP (VBZ:[770..777] appears)
                    (S
                      (NP-SBJ (-NONE-:[777..777] *))
                      (VP (TO:[778..780] to)
                        (VP (VB:[781..783] be)
                          (ADJP-PRD (JJ:[784..791] optimal))
                          (PP-3 (-NONE-:[791..791] *T*)))))))))
            (VP (VBP:[792..795] are) (RB:[796..799] not)
              (ADVP (RB:[800..807] clearly))
              (VP (VBN:[809..816] defined)
                (NP-2 (-NONE-:[816..816] *))))))))
    (.:[816..817] .)))

;sentence 7 Span:818..1051
;Almost all recent assays developed for the quantitative determination  of
;SSRIs and their metabolites in blood are based either on the separation of 
;SSRIs by high performance liquid chromatography (HPLC) or gas chromatography 
;(GC).
;[892..897]:substance:"SSRIs"
;[908..919]:substance:"metabolites"
;[968..973]:substance:"SSRIs"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (QP (RB:[818..824] Almost) (DT:[825..828] all))
        (JJ:[829..835] recent) (NNS:[836..842] assays))
      (VP (VBN:[843..852] developed)
        (NP (-NONE-:[852..852] *))
        (PP (IN:[853..856] for)
          (NP
            (NP (DT:[857..860] the) (JJ:[861..873] quantitative)
                (NN:[874..887] determination))
            (PP (IN:[889..891] of)
              (NP
                (NP (NNS:[892..897] SSRIs))
                (CC:[898..901] and)
                (NP (PRP$:[902..907] their) (NNS:[908..919] metabolites))))
            (PP-LOC (IN:[920..922] in)
              (NP (NN:[923..928] blood)))))))
    (VP (VBP:[929..932] are)
      (VP (VBN:[933..938] based)
        (NP-1 (-NONE-:[938..938] *))
        (UCP (CC:[939..945] either)
          (PP (IN:[946..948] on)
            (NP
              (NP (DT:[949..952] the) (NN:[953..963] separation))
              (PP (IN:[964..966] of)
                (NP (NNS:[968..973] SSRIs)))
              (PP-MNR (IN:[974..976] by)
                (NP
                  (NP
                    (NML (JJ:[977..981] high) (NN:[982..993] performance))
                    (JJ:[994..1000] liquid) (NN:[1001..1015] chromatography))
                  (NP (-LRB-:[1016..1017] -LRB-) (NN:[1017..1021] HPLC)
                      (-RRB-:[1021..1022] -RRB-))))))
          (CC:[1023..1025] or)
          (NP
            (NP (NN:[1026..1029] gas) (NN:[1030..1044] chromatography))
            (NP (-LRB-:[1046..1047] -LRB-) (NN:[1047..1049] GC)
                (-RRB-:[1049..1050] -RRB-))))))
    (.:[1050..1051] .)))

;sentence 8 Span:1052..1120
;Citalopram and fluoxetine have been introduced as racemic compounds.
;[1052..1062]:substance:"Citalopram"
;[1067..1077]:substance:"fluoxetine"
;[1102..1119]:substance:"racemic compounds"
(SENT
  (S
    (NP-SBJ-1 (NN:[1052..1062] Citalopram) (CC:[1063..1066] and)
              (NN:[1067..1077] fluoxetine))
    (VP (VBP:[1078..1082] have)
      (VP (VBN:[1083..1087] been)
        (VP (VBN:[1088..1098] introduced)
          (NP-1 (-NONE-:[1098..1098] *))
          (PP (IN:[1099..1101] as)
            (NP (JJ:[1102..1109] racemic) (NNS:[1110..1119] compounds))))))
    (.:[1119..1120] .)))

;sentence 9 Span:1121..1298
;There  are some differences in the pharmacological profile, metabolism and 
;pharmacokinetics between the enantiomers of the parent compounds and their 
;demethylated metabolites.
;[1226..1237]:substance:"enantiomers"
;[1252..1261]:substance:"compounds"
;[1273..1297]:substance:"demethylated metabolites"
(SENT
  (S
    (NP-SBJ (EX:[1121..1126] There))
    (VP (VBP:[1128..1131] are)
      (NP-SBJ (DT:[1132..1136] some) (NNS:[1137..1148] differences))
      (PP-LOC (IN:[1149..1151] in)
        (NP
          (NP (DT:[1152..1155] the)
            (NML
              (NML (JJ:[1156..1171] pharmacological) (NN:[1172..1179] profile))
              (,:[1179..1180] ,)
              (NML (NN:[1181..1191] metabolism))
              (CC:[1192..1195] and)
              (NML (NNS:[1197..1213] pharmacokinetics))))
          (PP (IN:[1214..1221] between)
            (NP
              (NP (DT:[1222..1225] the) (NNS:[1226..1237] enantiomers))
              (PP (IN:[1238..1240] of)
                (NP
                  (NP (DT:[1241..1244] the) (NN:[1245..1251] parent)
                      (NNS:[1252..1261] compounds))
                  (CC:[1262..1265] and)
                  (NP (PRP$:[1266..1271] their)
                     (VBN:[1273..1285] demethylated)
                     (NNS:[1286..1297] metabolites)))))))))
    (.:[1297..1298] .)))

;sentence 10 Span:1299..1386
;Stereoselective chromatographic methods for their  analysis in blood are now
;available.
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1299..1314] Stereoselective) (JJ:[1315..1330] chromatographic)
          (NNS:[1331..1338] methods))
      (PP (IN:[1339..1342] for)
        (NP (PRP$:[1343..1348] their) (NN:[1350..1358] analysis)))
      (PP (IN:[1359..1361] in)
        (NP (NN:[1362..1367] blood))))
    (VP (VBP:[1368..1371] are)
      (ADVP-TMP (RB:[1372..1375] now))
      (ADJP-PRD (JJ:[1376..1385] available)))
    (.:[1385..1386] .)))

;sentence 11 Span:1387..1602
;With regard to the SSRIs presently  available, no clearcut plasma
;concentration-clinical effectiveness relationship  in patients with
;depression has been shown, nor any threshold which defines  toxic
;concentrations.
;[1406..1411]:substance:"SSRIs"
(SENT
  (S
    (PP (IN:[1387..1391] With)
      (NP
        (NP (NN:[1392..1398] regard))
        (PP (TO:[1399..1401] to)
          (NP
            (NP (DT:[1402..1405] the) (NNS:[1406..1411] SSRIs))
            (ADJP (RB:[1412..1421] presently) (JJ:[1423..1432] available))))))
    (,:[1432..1433] ,)
    (NP-SBJ-3
      (NP (DT:[1434..1436] no) (JJ:[1437..1445] clearcut)
        (NML
          (NML (NN:[1446..1452] plasma) (NN:[1453..1466] concentration))
          (HYPH:[1466..1467] -)
          (NML (JJ:[1467..1475] clinical) (NN:[1476..1489] effectiveness)))
        (NN:[1490..1502] relationship))
      (PP-LOC (IN:[1504..1506] in)
        (NP
          (NP (NNS:[1507..1515] patients))
          (PP (IN:[1516..1520] with)
            (NP (NN:[1521..1531] depression)))))
      (NP-2 (-NONE-:[1531..1531] *ICH*)))
    (VP (VBZ:[1532..1535] has)
      (VP (VBN:[1536..1540] been)
        (VP (VBN:[1541..1546] shown)
          (NP-3 (-NONE-:[1546..1546] *))
          (,:[1546..1547] ,)
          (FRAG (CC:[1548..1551] nor)
            (NP-2
              (NP (DT:[1552..1555] any) (NN:[1556..1565] threshold))
              (SBAR
                (WHNP-1 (WDT:[1566..1571] which))
                (S
                  (NP-SBJ-1 (-NONE-:[1571..1571] *T*))
                  (VP (VBZ:[1572..1579] defines)
                    (NP (JJ:[1581..1586] toxic)
                        (NNS:[1587..1601] concentrations))))))))))
    (.:[1601..1602] .)))

;sentence 12 Span:1603..1711
;This may be explained by their low toxicity and use at  dosages where serious
;adverse effects do not appear.
(SENT
  (S
    (NP-SBJ-2 (DT:[1603..1607] This))
    (VP (MD:[1608..1611] may)
      (VP (VB:[1612..1614] be)
        (VP (VBN:[1615..1624] explained)
          (NP-2 (-NONE-:[1624..1624] *))
          (PP (IN:[1625..1627] by)
            (NP-LGS
              (NP (PRP$:[1628..1633] their)
                (NML
                  (NML
                    (ADJP-1 (JJ:[1634..1637] low))
                    (NN:[1638..1646] toxicity))
                  (CC:[1647..1650] and)
                  (NML
                    (ADJP-1 (-NONE-:[1650..1650] *P*))
                    (NN:[1651..1654] use))))
              (PP (IN:[1655..1657] at)
                (NP
                  (NP (NNS:[1659..1666] dosages))
                  (SBAR
                    (WHADVP-3 (WRB:[1667..1672] where))
                    (S
                      (NP-SBJ (JJ:[1673..1680] serious)
                              (JJ:[1681..1688] adverse)
                              (NNS:[1689..1696] effects))
                      (VP (VBP:[1697..1699] do) (RB:[1700..1703] not)
                        (VP (VB:[1704..1710] appear)
                          (ADVP-3 (-NONE-:[1710..1710] *T*)))))))))))))
    (.:[1710..1711] .)))

;sentence 13 Span:1712..1831
;SSRIs vary widely in their  qualitative and quantitative interaction with
;cytochrome P450 (CYP) isozymes in  the liver.
;[1712..1717]:substance:"SSRIs"
;[1786..1816]:cyp450:"cytochrome P450 (CYP) isozymes"
(SENT
  (S
    (NP-SBJ (NNS:[1712..1717] SSRIs))
    (VP (VBP:[1718..1722] vary)
      (ADVP (RB:[1723..1729] widely))
      (PP (IN:[1730..1732] in)
        (NP
          (NP (PRP$:[1733..1738] their)
            (NML
              (NML (JJ:[1740..1751] qualitative)
                (NML-1 (-NONE-:[1751..1751] *P*)))
              (CC:[1752..1755] and)
              (NML (JJ:[1756..1768] quantitative)
                (NML-1 (NN:[1769..1780] interaction)))))
          (PP (IN:[1781..1785] with)
            (NP
              (NML
                (NML (NN:[1786..1796] cytochrome) (NN:[1797..1801] P450))
                (NML (-LRB-:[1802..1803] -LRB-) (NN:[1803..1806] CYP)
                     (-RRB-:[1806..1807] -RRB-)))
              (NNS:[1808..1816] isozymes)))))
      (PP-LOC (IN:[1817..1819] in)
        (NP (DT:[1821..1824] the) (NN:[1825..1830] liver))))
    (.:[1830..1831] .)))

;sentence 14 Span:1832..1972
;CYP2D6 is inhibited by SSRIs, in order of decreasing potency  paroxetine,
;norfluoxetine, fluoxetine, sertraline, citalopram and fluvoxamine.
;[1832..1838]:cyp450:"CYP2D6"
;[1855..1860]:substance:"SSRIs"
;[1894..1904]:substance:"paroxetine"
;[1906..1919]:substance:"norfluoxetine"
;[1921..1931]:substance:"fluoxetine"
;[1933..1943]:substance:"sertraline"
;[1945..1955]:substance:"citalopram"
;[1960..1971]:substance:"fluvoxamine"
(SENT
  (S
    (NP-SBJ-1 (NN:[1832..1838] CYP2D6))
    (VP (VBZ:[1839..1841] is)
      (VP (VBN:[1842..1851] inhibited)
        (NP-1 (-NONE-:[1851..1851] *))
        (PP (IN:[1852..1854] by)
          (NP-LGS
            (NP (NNS:[1855..1860] SSRIs))
            (,:[1860..1861] ,)
            (NP
              (PP (IN:[1862..1864] in)
                (NP
                  (NP (NN:[1865..1870] order))
                  (PP (IN:[1871..1873] of)
                    (NP (VBG:[1874..1884] decreasing) (NN:[1885..1892] potency)))))
              (NN:[1894..1904] paroxetine) (,:[1904..1905] ,)
               (NN:[1906..1919] norfluoxetine) (,:[1919..1920] ,)
               (NN:[1921..1931] fluoxetine) (,:[1931..1932] ,)
               (NN:[1933..1943] sertraline) (,:[1943..1944] ,)
               (NN:[1945..1955] citalopram) (CC:[1956..1959] and)
               (NN:[1960..1971] fluvoxamine))))))
    (.:[1971..1972] .)))

;sentence 15 Span:1974..2091
;This may have clinical consequences with some but not all SSRIs, when they
;are  taken with tricyclic antidepressants.
;[2032..2037]:substance:"SSRIs"
;[2065..2090]:substance:"tricyclic antidepressants"
(SENT
  (S
    (NP-SBJ (DT:[1974..1978] This))
    (VP (MD:[1979..1982] may)
      (VP (VB:[1983..1987] have)
        (NP (JJ:[1988..1996] clinical) (NNS:[1997..2009] consequences))
        (PP (IN:[2010..2014] with)
          (NP
            (NP (DT:[2015..2019] some)
              (NML-2 (-NONE-:[2019..2019] *P*)))
            (CONJP (CC:[2020..2023] but) (RB:[2024..2027] not))
            (NP (DT:[2028..2031] all)
              (NML-2 (NNS:[2032..2037] SSRIs)))))
        (,:[2037..2038] ,)
        (SBAR-ADV
          (WHADVP-3 (WRB:[2039..2043] when))
          (S
            (NP-SBJ-1 (PRP:[2044..2048] they))
            (VP (VBP:[2049..2052] are)
              (VP (VBN:[2054..2059] taken)
                (NP-1 (-NONE-:[2059..2059] *))
                (PP (IN:[2060..2064] with)
                  (NP (JJ:[2065..2074] tricyclic)
                      (NNS:[2075..2090] antidepressants)))
                (ADVP-TMP-3 (-NONE-:[2090..2090] *T*))))))))
    (.:[2090..2091] .)))

;sentence 16 Span:2092..2215
;Except for citalopram and paroxetine,  little is known about the enzymes
;which control the biotransformation of the  SSRIs.
;[2103..2113]:substance:"citalopram"
;[2118..2128]:substance:"paroxetine"
;[2157..2164]:substance:"enzymes"
;[2209..2214]:substance:"SSRIs"
(SENT
  (S
    (PP (IN:[2092..2098] Except)
      (PP (IN:[2099..2102] for)
        (NP (NN:[2103..2113] citalopram) (CC:[2114..2117] and)
            (NN:[2118..2128] paroxetine))))
    (,:[2128..2129] ,)
    (NP-SBJ-2
      (ADJP (JJ:[2131..2137] little)))
    (VP (VBZ:[2138..2140] is)
      (VP (VBN:[2141..2146] known)
        (NP-2 (-NONE-:[2146..2146] *))
        (PP (IN:[2147..2152] about)
          (NP
            (NP (DT:[2153..2156] the) (NNS:[2157..2164] enzymes))
            (SBAR
              (WHNP-1 (WDT:[2165..2170] which))
              (S
                (NP-SBJ-1 (-NONE-:[2170..2170] *T*))
                (VP (VBP:[2171..2178] control)
                  (NP
                    (NP (DT:[2179..2182] the)
                        (NN:[2183..2200] biotransformation))
                    (PP (IN:[2201..2203] of)
                      (NP (DT:[2204..2207] the) (NNS:[2209..2214] SSRIs)))))))))))
    (.:[2214..2215] .)))

;sentence 17 Span:2216..2334
;There have been many reports on marked pharmacokinetic interactions  between
;fluoxetine and tricyclic antidepressants.
;[2293..2303]:substance:"fluoxetine"
;[2308..2333]:substance:"tricyclic antidepressants"
(SENT
  (S
    (NP-SBJ (EX:[2216..2221] There))
    (VP (VBP:[2222..2226] have)
      (VP (VBN:[2227..2231] been)
        (NP-PRD
          (NP (JJ:[2232..2236] many) (NNS:[2237..2244] reports))
          (PP (IN:[2245..2247] on)
            (NP
              (NP (VBN:[2248..2254] marked) (JJ:[2255..2270] pharmacokinetic)
                  (NNS:[2271..2283] interactions))
              (PP (IN:[2285..2292] between)
                (NP
                  (NP (NN:[2293..2303] fluoxetine))
                  (CC:[2304..2307] and)
                  (NP (JJ:[2308..2317] tricyclic)
                      (NNS:[2318..2333] antidepressants)))))))))
    (.:[2333..2334] .)))

;sentence 18 Span:2335..2420
;Fluoxetine has a stronger  effect on their hydroxylation than on their
;demethylation.
;[2335..2345]:substance:"Fluoxetine"
(SENT
  (S
    (NP-SBJ (NN:[2335..2345] Fluoxetine))
    (VP (VBZ:[2346..2349] has)
      (NP
        (NP (DT:[2350..2351] a) (JJR:[2352..2360] stronger)
            (NN:[2362..2368] effect))
        (PP (IN:[2369..2371] on)
          (NP (PRP$:[2372..2377] their) (NN:[2378..2391] hydroxylation)))
        (PP (IN:[2392..2396] than)
          (PP (IN:[2397..2399] on)
            (NP (PRP$:[2400..2405] their) (NN:[2406..2419] demethylation))))))
    (.:[2419..2420] .)))

;sentence 19 Span:2421..2544
;Interactions observed  between fluoxetine and alprazolam, midazolam and
;carbamazepine seem to occur on  the level of CYP3A.
;[2452..2462]:substance:"fluoxetine"
;[2467..2477]:substance:"alprazolam"
;[2479..2488]:substance:"midazolam"
;[2493..2506]:substance:"carbamazepine"
;[2538..2543]:cyp450:"CYP3A"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[2421..2433] Interactions))
      (VP (VBN:[2434..2442] observed)
        (NP (-NONE-:[2442..2442] *))
        (PP (IN:[2444..2451] between)
          (NP
            (NP (NN:[2452..2462] fluoxetine) (CC:[2463..2466] and)
                (NN:[2467..2477] alprazolam))
            (,:[2477..2478] ,)
            (NP (NN:[2479..2488] midazolam) (CC:[2489..2492] and)
                (NN:[2493..2506] carbamazepine))))))
    (VP (VBP:[2507..2511] seem)
      (S
        (NP-SBJ-1 (-NONE-:[2511..2511] *))
        (VP (TO:[2512..2514] to)
          (VP (VB:[2515..2520] occur)
            (PP (IN:[2521..2523] on)
              (NP
                (NP (DT:[2525..2528] the) (NN:[2529..2534] level))
                (PP (IN:[2535..2537] of)
                  (NP (NN:[2538..2543] CYP3A)))))))))
    (.:[2543..2544] .)))

;sentence 20 Span:2545..2674
;Fluvoxamine strongly inhibits the N-demethylation of some  tricyclic
;antidepressants of the tertiary amine type and of clozapine.
;[2545..2556]:substance:"Fluvoxamine"
;[2604..2629]:substance:"tricyclic antidepressants"
;[2664..2673]:substance:"clozapine"
(SENT
  (S
    (NP-SBJ (NN:[2545..2556] Fluvoxamine))
    (ADVP (RB:[2557..2565] strongly))
    (VP (VBZ:[2566..2574] inhibits)
      (NP
        (NP (DT:[2575..2578] the) (NN:[2579..2594] N-demethylation))
        (PP (IN:[2595..2597] of)
          (NP
            (NP (DT:[2598..2602] some)
               (JJ:[2604..2613] tricyclic) (NNS:[2614..2629] antidepressants))
            (PP
              (PP (IN:[2630..2632] of)
                (NP (DT:[2633..2636] the) (JJ:[2637..2645] tertiary)
                    (NN:[2646..2651] amine) (NN:[2652..2656] type)))
              (CC:[2657..2660] and)
              (PP (IN:[2661..2663] of)
                (NP (NN:[2664..2673] clozapine))))))))
    (.:[2673..2674] .)))

;sentence 21 Span:2675..2855
;This may  lead to adverse effects but augmentation with fluvoxamine can also
;improve  response in very rapid metabolisers, as it increases the
;bioavailability of the  comedication.
;[2731..2742]:substance:"fluvoxamine"
;[2784..2796]:substance:"metabolisers"
(SENT
  (S
    (S
      (NP-SBJ (DT:[2675..2679] This))
      (VP (MD:[2680..2683] may)
        (VP (VB:[2685..2689] lead)
          (PP-CLR (TO:[2690..2692] to)
            (NP (JJ:[2693..2700] adverse) (NNS:[2701..2708] effects))))))
    (CC:[2709..2712] but)
    (S
      (NP-SBJ
        (NP (NN:[2713..2725] augmentation))
        (PP (IN:[2726..2730] with)
          (NP (NN:[2731..2742] fluvoxamine))))
      (VP (MD:[2743..2746] can)
        (ADVP (RB:[2747..2751] also))
        (VP (VB:[2752..2759] improve)
          (NP (NN:[2761..2769] response))
          (PP-LOC (IN:[2770..2772] in)
            (NP
              (ADJP (RB:[2773..2777] very) (JJ:[2778..2783] rapid))
              (NNS:[2784..2796] metabolisers)))
          (,:[2796..2797] ,)
          (SBAR-ADV (IN:[2798..2800] as)
            (S
              (NP-SBJ (PRP:[2801..2803] it))
              (VP (VBZ:[2804..2813] increases)
                (NP
                  (NP (DT:[2814..2817] the) (NN:[2818..2833] bioavailability))
                  (PP (IN:[2834..2836] of)
                    (NP (DT:[2837..2840] the) (NN:[2842..2854] comedication))))))))))
    (.:[2854..2855] .)))

;sentence 22 Span:2856..2976
;Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19,  CYP2D6 and
;CYP1A1, but it is also an inhibitor of CYP3A.
;[2856..2867]:substance:"Fluvoxamine"
;[2902..2908]:cyp450:"CYP1A2"
;[2910..2917]:cyp450:"CYP2C19"
;[2920..2926]:cyp450:"CYP2D6"
;[2931..2937]:cyp450:"CYP1A1"
;[2957..2966]:substance:"inhibitor"
;[2970..2975]:cyp450:"CYP3A"
(SENT
  (S
    (S
      (NP-SBJ (NN:[2856..2867] Fluvoxamine))
      (VP (VBZ:[2868..2876] inhibits)
        (NP
          (PP (IN:[2877..2881] with)
            (NP (VBG:[2882..2892] decreasing) (NN:[2893..2900] potency)))
          (,:[2900..2901] ,) (NN:[2902..2908] CYP1A2) (,:[2908..2909] ,)
           (NN:[2910..2917] CYP2C19) (,:[2917..2918] ,) (NN:[2920..2926] CYP2D6)
           (CC:[2927..2930] and) (NN:[2931..2937] CYP1A1))))
    (,:[2937..2938] ,) (CC:[2939..2942] but)
    (S
      (NP-SBJ (PRP:[2943..2945] it))
      (VP (VBZ:[2946..2948] is)
        (ADVP (RB:[2949..2953] also))
        (NP-PRD
          (NP (DT:[2954..2956] an) (NN:[2957..2966] inhibitor))
          (PP (IN:[2967..2969] of)
            (NP (NN:[2970..2975] CYP3A))))))
    (.:[2975..2976] .)))

;sentence 23 Span:2977..3083
;Fluoxetine and  fluvoxamine have shown to increase methadone plasma
;concentrations in dependent  patients.
;[2977..2987]:substance:"Fluoxetine"
;[2993..3004]:substance:"fluvoxamine"
;[3028..3037]:substance:"methadone"
(SENT
  (S
    (NP-SBJ-1 (NN:[2977..2987] Fluoxetine) (CC:[2988..2991] and)
              (NN:[2993..3004] fluvoxamine))
    (VP (VBP:[3005..3009] have)
      (VP (VBN:[3010..3015] shown)
        (S
          (NP-SBJ-1 (-NONE-:[3015..3015] *))
          (VP (TO:[3016..3018] to)
            (VP (VB:[3019..3027] increase)
              (NP (NN:[3028..3037] methadone) (NN:[3038..3044] plasma)
                  (NNS:[3045..3059] concentrations))
              (PP-LOC (IN:[3060..3062] in)
                (NP (JJ:[3063..3072] dependent) (NNS:[3074..3082] patients))))))))
    (.:[3082..3083] .)))

;sentence 24 Span:3084..3219
;Some authors warn about a combination of monoamine oxidase (MAO)  inhibitors
;with SSRIs, as this could lead to a serotonergic syndrome.
;[3125..3160]:substance:"monoamine oxidase (MAO)  inhibitors"
;[3166..3171]:substance:"SSRIs"
(SENT
  (S
    (NP-SBJ (DT:[3084..3088] Some) (NNS:[3089..3096] authors))
    (VP (VBP:[3097..3101] warn)
      (PP (IN:[3102..3107] about)
        (NP
          (NP (DT:[3108..3109] a) (NN:[3110..3121] combination))
          (PP (IN:[3122..3124] of)
            (NP
              (NML
                (NML (NN:[3125..3134] monoamine) (NN:[3135..3142] oxidase))
                (NML (-LRB-:[3143..3144] -LRB-) (NN:[3144..3147] MAO)
                     (-RRB-:[3147..3148] -RRB-)))
              (NNS:[3150..3160] inhibitors)))
          (PP (IN:[3161..3165] with)
            (NP (NNS:[3166..3171] SSRIs)))))
      (,:[3171..3172] ,)
      (SBAR-ADV (IN:[3173..3175] as)
        (S
          (NP-SBJ (DT:[3176..3180] this))
          (VP (MD:[3181..3186] could)
            (VP (VB:[3187..3191] lead)
              (PP-CLR (TO:[3192..3194] to)
                (NP (DT:[3195..3196] a) (JJ:[3197..3209] serotonergic)
                    (NN:[3210..3218] syndrome))))))))
    (.:[3218..3219] .)))

;sentence 25 Span:3220..3406
;Studies  with healthy volunteers suggest, however, that a combination of
;moclobemide and  SSRIs, such as fluvoxamine, should not present serious risks
;in promoting a  serotonin syndrome.
;[3293..3304]:substance:"moclobemide"
;[3310..3315]:substance:"SSRIs"
;[3325..3336]:substance:"fluvoxamine"
;[3387..3396]:substance:"serotonin"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[3220..3227] Studies))
      (PP (IN:[3229..3233] with)
        (NP (JJ:[3234..3241] healthy) (NNS:[3242..3252] volunteers))))
    (VP (VBP:[3253..3260] suggest) (,:[3260..3261] ,)
      (ADVP (RB:[3262..3269] however))
      (,:[3269..3270] ,)
      (SBAR (IN:[3271..3275] that)
        (S
          (NP-SBJ
            (NP (DT:[3276..3277] a) (NN:[3278..3289] combination))
            (PP (IN:[3290..3292] of)
              (NP
                (NP (NN:[3293..3304] moclobemide))
                (CC:[3305..3308] and)
                (NP
                  (NP (NNS:[3310..3315] SSRIs))
                  (,:[3315..3316] ,)
                  (PP (JJ:[3317..3321] such)
                    (PP (IN:[3322..3324] as)
                      (NP (NN:[3325..3336] fluvoxamine))))))))
          (,:[3336..3337] ,)
          (VP (MD:[3338..3344] should) (RB:[3345..3348] not)
            (VP (VB:[3349..3356] present)
              (NP (JJ:[3357..3364] serious) (NNS:[3365..3370] risks))
              (PP (IN:[3371..3373] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[3373..3373] *))
                  (VP (VBG:[3374..3383] promoting)
                    (NP (DT:[3384..3385] a) (NN:[3387..3396] serotonin)
                        (NN:[3397..3405] syndrome))))))))))
    (.:[3405..3406] .)))

;sentence 26 Span:3407..3630
;A combination of moclobemide and fluvoxamine has  successfully been used in
;refractory depression, but more studies are needed,  including
;plasma-concentration monitoring, before this combined treatment can be 
;recommended.
;[3424..3435]:substance:"moclobemide"
;[3440..3451]:substance:"fluvoxamine"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (DT:[3407..3408] A) (NN:[3409..3420] combination))
        (PP (IN:[3421..3423] of)
          (NP (NN:[3424..3435] moclobemide) (CC:[3436..3439] and)
              (NN:[3440..3451] fluvoxamine))))
      (VP (VBZ:[3452..3455] has)
        (ADVP (RB:[3457..3469] successfully))
        (VP (VBN:[3470..3474] been)
          (VP (VBN:[3475..3479] used)
            (NP-2 (-NONE-:[3479..3479] *))
            (PP (IN:[3480..3482] in)
              (NP (JJ:[3483..3493] refractory) (NN:[3494..3504] depression)))))))
    (,:[3504..3505] ,) (CC:[3506..3509] but)
    (S
      (NP-SBJ-3
        (NP (JJR:[3510..3514] more) (NNS:[3515..3522] studies))
        (PP-4 (-NONE-:[3522..3522] *ICH*)))
      (VP (VBP:[3523..3526] are)
        (VP (VBN:[3527..3533] needed)
          (NP-3 (-NONE-:[3533..3533] *))
          (,:[3533..3534] ,)
          (PP-4 (VBG:[3536..3545] including)
            (NP
              (NML (NN:[3546..3552] plasma) (HYPH:[3552..3553] -)
                   (NN:[3553..3566] concentration))
              (NN:[3567..3577] monitoring)))
          (,:[3577..3578] ,)
          (SBAR-TMP (IN:[3579..3585] before)
            (S
              (NP-SBJ-1 (DT:[3586..3590] this) (VBN:[3591..3599] combined)
                        (NN:[3600..3609] treatment))
              (VP (MD:[3610..3613] can)
                (VP (VB:[3614..3616] be)
                  (NP (VBN:[3618..3629] recommended)
                    (NP-1 (-NONE-:[3629..3629] *))))))))))
    (.:[3629..3630] .)))

;sentence 27 Span:3631..3712
;Paroxetine is a substrate of CYP2D6, but other enzyme(s) could also  be
;involved.
;[3631..3641]:substance:"Paroxetine"
;[3647..3656]:substance:"substrate"
;[3660..3666]:cyp450:"CYP2D6"
;[3678..3687]:substance:"enzyme(s)"
(SENT
  (S
    (S
      (NP-SBJ (NN:[3631..3641] Paroxetine))
      (VP (VBZ:[3642..3644] is)
        (NP
          (NP (DT:[3645..3646] a) (NN:[3647..3656] substrate))
          (PP (IN:[3657..3659] of)
            (NP (NN:[3660..3666] CYP2D6))))))
    (,:[3666..3667] ,) (CC:[3668..3671] but)
    (S
      (NP-SBJ-1 (JJ:[3672..3677] other) (NNS:[3678..3687] enzyme-LRB-s-RRB-))
      (VP (MD:[3688..3693] could)
        (ADVP (RB:[3694..3698] also))
        (VP (VB:[3700..3702] be)
          (VP (VBN:[3703..3711] involved)
            (NP-1 (-NONE-:[3711..3711] *))))))
    (.:[3711..3712] .)))

;sentence 28 Span:3713..3822
;Its pharmacokinetics are linear in poor metabolisers of sparteine,  and
;non-linear in extensive metabolisers.
;[3753..3765]:substance:"metabolisers"
;[3769..3778]:substance:"sparteine"
;[3809..3821]:substance:"metabolisers"
(SENT
  (S
    (NP-SBJ (PRP$:[3713..3716] Its) (NNS:[3717..3733] pharmacokinetics))
    (VP
      (VP (VBP:[3734..3737] are)
        (ADJP-PRD=2 (JJ:[3738..3744] linear))
        (PP-LOC=3 (IN:[3745..3747] in)
          (NP
            (NP (JJ:[3748..3752] poor) (NNS:[3753..3765] metabolisers))
            (PP (IN:[3766..3768] of)
              (NP (NN:[3769..3778] sparteine))))))
      (,:[3778..3779] ,) (CC:[3781..3784] and)
      (VP
        (ADJP-PRD=2 (AFX:[3785..3788] non) (HYPH:[3788..3789] -)
                    (JJ:[3789..3795] linear))
        (PP-LOC=3 (IN:[3796..3798] in)
          (NP (JJ:[3799..3808] extensive) (NNS:[3809..3821] metabolisers)))))
    (.:[3821..3822] .)))

;sentence 29 Span:3823..4010
;Due to its potent CYP2D6 inhibiting  properties, comedication with this SSRI
;can lead to an increase of tricyclic  antidepressants in plasma, as shown
;with amitriptyline and trimipramine.
;[3841..3847]:cyp450:"CYP2D6"
;[3895..3899]:substance:"SSRI"
;[3927..3953]:substance:"tricyclic  antidepressants"
;[3979..3992]:substance:"amitriptyline"
;[3997..4009]:substance:"trimipramine"
(SENT
  (S
    (PP (JJ:[3823..3826] Due)
      (PP (TO:[3827..3829] to)
        (NP (PRP$:[3830..3833] its) (JJ:[3834..3840] potent)
          (NML (NN:[3841..3847] CYP2D6) (VBG:[3848..3858] inhibiting))
          (NNS:[3860..3870] properties))))
    (,:[3870..3871] ,)
    (NP-SBJ
      (NP (NN:[3872..3884] comedication))
      (PP (IN:[3885..3889] with)
        (NP (DT:[3890..3894] this) (NN:[3895..3899] SSRI))))
    (VP (MD:[3900..3903] can)
      (VP (VB:[3904..3908] lead)
        (PP-CLR (TO:[3909..3911] to)
          (NP
            (NP (DT:[3912..3914] an) (NN:[3915..3923] increase))
            (PP (IN:[3924..3926] of)
              (NP (JJ:[3927..3936] tricyclic) (NNS:[3938..3953] antidepressants)))))
        (PP (IN:[3954..3956] in)
          (NP (NN:[3957..3963] plasma)))
        (,:[3963..3964] ,)
        (PP (IN:[3965..3967] as)
          (S-NOM
            (NP-SBJ-1 (-NONE-:[3967..3967] *))
            (VP (VBN:[3968..3973] shown)
              (NP-1 (-NONE-:[3973..3973] *))
              (PP (IN:[3974..3978] with)
                (NP (NN:[3979..3992] amitriptyline) (CC:[3993..3996] and)
                    (NN:[3997..4009] trimipramine))))))))
    (.:[4009..4010] .)))

;sentence 30 Span:4011..4107
;CYP3A  has been claimed to be involved in the biotransformation of sertraline
;to  norsertraline.
;[4011..4016]:cyp450:"CYP3A"
;[4078..4088]:substance:"sertraline"
;[4093..4106]:substance:"norsertraline"
(SENT
  (S
    (NP-SBJ-1 (NN:[4011..4016] CYP3A))
    (VP (VBZ:[4018..4021] has)
      (VP (VBN:[4022..4026] been)
        (VP (VBN:[4027..4034] claimed)
          (S
            (NP-SBJ-1 (-NONE-:[4034..4034] *))
            (VP (TO:[4035..4037] to)
              (VP (VB:[4038..4040] be)
                (VP (VBN:[4041..4049] involved)
                  (NP-1 (-NONE-:[4049..4049] *))
                  (PP-CLR (IN:[4050..4052] in)
                    (NP
                      (NP (DT:[4053..4056] the)
                          (NN:[4057..4074] biotransformation))
                      (PP (IN:[4075..4077] of)
                        (NP (NN:[4078..4088] sertraline)))
                      (PP (TO:[4089..4091] to)
                        (NP (NN:[4093..4106] norsertraline))))))))))))
    (.:[4106..4107] .)))

;sentence 31 Span:4108..4234
;Clinical investigations (with desipramine) confirmed in vitro  findings that
;CYP2D6 inhibition by sertraline is only moderate.
;[4138..4149]:substance:"desipramine"
;[4185..4191]:cyp450:"CYP2D6"
;[4206..4216]:substance:"sertraline"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[4108..4116] Clinical) (NNS:[4117..4131] investigations))
      (PRN (-LRB-:[4132..4133] -LRB-)
        (PP (IN:[4133..4137] with)
          (NP (NN:[4138..4149] desipramine)))
        (-RRB-:[4149..4150] -RRB-)))
    (VP (VBD:[4151..4160] confirmed)
      (NP
        (ADJP (FW:[4161..4163] in) (FW:[4164..4169] vitro))
        (NNS:[4171..4179] findings)
        (SBAR (IN:[4180..4184] that)
          (S
            (NP-SBJ
              (NP (NN:[4185..4191] CYP2D6) (NN:[4192..4202] inhibition))
              (PP (IN:[4203..4205] by)
                (NP (NN:[4206..4216] sertraline))))
            (VP (VBZ:[4217..4219] is)
              (ADVP (RB:[4220..4224] only))
              (ADJP-PRD (JJ:[4225..4233] moderate)))))))
    (.:[4233..4234] .)))

;section 32 Span:4235..4256
;(ABSTRACT  TRUNCATED)
(SEC
  (PRN (-LRB-:[4235..4236] -LRB-)
    (NP (NN:[4236..4244] ABSTRACT) (VBN:[4246..4255] TRUNCATED))
    (-RRB-:[4255..4256] -RRB-)))

;section 33 Span:4260..4278
;Publication Types:
(SEC
  (FRAG (NNP:[4260..4271] Publication) (NNP:[4272..4277] Types)
        (::[4277..4278] :)))

;section 34 Span:4284..4290
;Review
(SEC
  (FRAG (NNP:[4284..4290] Review)))

;section 35 Span:4296..4312
;Review, Tutorial
(SEC
  (FRAG (NNP:[4296..4302] Review) (,:[4302..4303] ,) (NNP:[4304..4312] Tutorial)))

;section 36 Span:4316..4360
;PMID: 8968657 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[4316..4320] PMID) (::[4320..4321] :) (CD:[4322..4329] 8968657)
        (NN:[4330..4331] -LSB-) (NNP:[4331..4337] PubMed) (::[4338..4339] -)
        (NN:[4340..4347] indexed) (IN:[4348..4351] for)
        (NNP:[4352..4360] MEDLINE-RSB-)))
